Effect of Hip Extension Mobilization on Functional Disability in Patients With Spondylolisthesis (EM)

April 17, 2026 updated by: Alaa Ahmed Kazamel, Cairo University
this study will be conducted to investigate the effect of hip extension mobilization on lumber disability, pain and flexion range of motion in patients with spondylolisthesis

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Spondylolisthesis is a kind of low back pain (LBP) that involves displacement of one vertebral body relative to the vertebra below it. Spondylolisthesis is derived from the Greek words spondylosis, which means vertebra, and olisthisis, which means slippage. The displacement of the cranial vertebra can be anterior (also known as anterolisthesis), lateral, or posterior (retrolisthesis) to the more caudal vertebra., most commonly occurring as an anterior slippage at the lumbosacral junction(L5-S1). The condition can result from several etiologies including congenital, isthmic, degenerative, traumatic, or pathologic causes. The clinical presentation of spondylolisthesis encompasses a broad spectrum, ranging from asymptomatic cases to those involving debilitating pain, neural compromise, and functional limitations. Degenerative spondylolisthesis (DS) predominantly affects older adults, with a marked predilection for females. A cross-sectional epidemiological survey involving over 4,000 patients reported a prevalence of 2.7% in men and 8.4% in women, underscoring a significant sex disparity.The most common site for degenerative spondylolisthesis is the L5 to S1 level. Mobilization increases hip range of motion, decreases pain and improves hip function more than non-weight bearing exercises.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
32

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Chronic female Patients diagnosed as grade 1 lumbar degenerative spondylolisthesis (anterolisthesis) referred from Orthopedists was confirmed by lumbosacral x-ray
  • Patients age ranged from 40 to 60 years.
  • BMI(25:35)
  • Ambulant patient with or without cane.
  • Cooperative patients with ability to understand instructions and follow simple verbal commands.

Exclusion Criteria:

  • Osteoporosis.
  • Pregnancy.
  • Signs consistent with nerve root compression (reproduction of low-back or leg pain with a straight leg raise at less than 45°, muscle weakness involving a major muscle group of the lower extremity, diminished lower extremity muscle stretch reflex, or diminished or absent sensation to pinprick in any lower extremity dermatome).
  • General tumors, spinal tumor, fracture, cauda equina syndrome, and previous surgery.
  • Other causes of spondylolisthesis.
  • Patients with (BMI ≥ 35)
  • Severe or life-threatening psychiatric illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: hip extension mobilization
Sixteen patients received hip extension mobilization with conventional treatment (William spinal flexion exercises and TENS) three times per week for one month.
Other: hip extension mobilization

the patients will receive hip extension mobilization to increase hip extension range of motion; the therapist applies an anterior glide mobilization-usually with the patient in a prone position. The patient is positioned in prone at the edge of the table. The hip is then flexed, abducted, and externally rotated into position as tolerated by the patient, and the foot is placed next to the contralateral knee. Impart anterior mobilization through the greater trochanter. The therapist applies a grade IV mobilization in a posterior to anterior direction to target the anterior hip.

The mobilizing hand applies a downward ward force through an extended elbow; body weight exerts the force+ cinentional treatment

Other: conventional treatment
Each subject will be given treatment of 30-40 minute session of William flexion exercises. The seven variations of Williams's exercises include (Pelvic tilt, single knee to chest, double knee to chest, half sit-up, hamstring stretch, hip flexor stretches, and squat). in additionn, The TENS electrodes are typically placed bilaterally along the lumbar paraspinal region directly over the painful area. The frequency of the output was set at 4 to 8 Hz. Continuous type used.
Active Comparator: conventional treatment
Sixteen patients received conventional treatment in the form of William's spinal flexion exercises and TENS three times per week for one month.
Other: conventional treatment
Each subject will be given treatment of 30-40 minute session of William flexion exercises. The seven variations of Williams's exercises include (Pelvic tilt, single knee to chest, double knee to chest, half sit-up, hamstring stretch, hip flexor stretches, and squat). in additionn, The TENS electrodes are typically placed bilaterally along the lumbar paraspinal region directly over the painful area. The frequency of the output was set at 4 to 8 Hz. Continuous type used.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
low back disability
Time Frame: up to four weeks
Arabic version of Roland Morris Disability will be used to assess low back disability. it is a valid, reliable 24-item tool used to assess physical disability in patients with low back pain (LBP). It has been culturally adapted to Modern Standard Arabic, with a score ranging from 0 to 24, where higher scores indicate greater functional disability.
up to four weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
pain intensity
Time Frame: up to four weeks
The visual analogie scale will be used to assess pain intensity. it is a one-dimensional instrument used to assess subjective pain intensity. It comprises a 10-cm (100-mm) line; with 0 refer to no pain while 100mm refer to extreme pain.
up to four weeks
lumbar flexion range of motion
Time Frame: up to four weeks
The BROM device will be used for lumbar flexion ROM.
up to four weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 25, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 17, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 17, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 23, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 23, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • P.T.REC/012/005861

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings